BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 8819246)

  • 1. High purity factor IX and prothrombin complex concentrate (PCC): pharmacokinetics and evidence that factor IXa is the thrombogenic trigger in PCC.
    Philippou H; Adami A; Lane DA; MacGregor IR; Tuddenham EG; Lowe GD; Rumley A; Ludlam CA
    Thromb Haemost; 1996 Jul; 76(1):23-8. PubMed ID: 8819246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics, thrombogenicity and safety of a double viral inactivated factor IX concentrate compared with a prothrombin complex concentrate.
    Ruiz-Sáez A; Hong A; Arguello A; Echenagucia M; Boadas A; Fabbrizzi F; Minichilli F; Bosch NB
    Haemophilia; 2005 Nov; 11(6):583-8. PubMed ID: 16236107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cross-over pharmacokinetic study of a double viral inactivated factor IX concentrate (15 nm filtration and SD) compared to a SD factor IX concentrate.
    Goudemand J; Peynet J; Chambost H; Négrier C; Briquel ME; Claeyssens S; Derlon-Borel A; Guérois C; Caron C; Scherrmann JM; Debray M; Bridey F
    Thromb Haemost; 1998 Dec; 80(6):919-24. PubMed ID: 9869161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of Beriplex P/N prothrombin complex concentrate in healthy volunteers.
    Ostermann H; Haertel S; Knaub S; Kalina U; Jung K; Pabinger I
    Thromb Haemost; 2007 Oct; 98(4):790-7. PubMed ID: 17938803
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic study of a high-purity factor IX concentrate (Factor IX Grifols) with a 6-month follow up in previously treated patients with severe haemophilia B.
    Aznar JA; Cabrera N; Matysiak M; Zawilska K; Gercheva L; Antonov A; Montañés M; Páez AM; Lissitchkov T
    Haemophilia; 2009 Nov; 15(6):1243-8. PubMed ID: 19659601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. No activation of the common pathway of the coagulation cascade after a highly purified factor IX concentrate.
    Mannucci PM; Bauer KA; Gringeri A; Barzegar S; Santagostino E; Tradati FC; Rosenberg RD
    Br J Haematol; 1991 Dec; 79(4):606-11. PubMed ID: 1772782
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of coagulation equilibrium at baseline and during factor VIII and factor IX replacement in haemophiliacs.
    Négrier C; Menart C; Attali O; Petit PY; Lienhart A; Dechavanne M; Ingerslev J
    Blood Coagul Fibrinolysis; 1998 Mar; 9 Suppl 1():S135-41. PubMed ID: 9819045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thrombin generation is not increased in the blood of hemophilia B patients after the infusion of a purified factor IX concentrate.
    Mannucci PM; Bauer KA; Gringeri A; Barzegar S; Bottasso B; Simoni L; Rosenberg RD
    Blood; 1990 Dec; 76(12):2540-5. PubMed ID: 2265248
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of high purity factor IX concentrates and a prothrombin complex concentrate in a canine model of thrombogenicity.
    MacGregor IR; Ferguson JM; McLaughlin LF; Burnouf T; Prowse CV
    Thromb Haemost; 1991 Nov; 66(5):609-13. PubMed ID: 1803625
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduced coagulation activation following infusion of a highly purified factor IX concentrate compared to a prothrombin complex concentrate.
    Hampton KK; Preston FE; Lowe GD; Walker ID; Sampson B
    Br J Haematol; 1993 Jun; 84(2):279-84. PubMed ID: 8398831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A cross-over pharmacokinetic and thrombogenicity study of a prothrombin complex concentrate and a purified factor IX concentrate.
    Thomas DP; Hampton KK; Dasani H; Lee CA; Giangrande PL; Harman C; Lee ML; Preston FE
    Br J Haematol; 1994 Aug; 87(4):782-8. PubMed ID: 7986719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Markers of hypercoagulability in patients with hemophilia B given repeated, large doses of factor IX concentrates during and after surgery.
    Santagostino E; Mannucci PM; Gringeri A; Tagariello G; Baudo F; Bauer KA; Rosenberg RD
    Thromb Haemost; 1994 Jun; 71(6):737-40. PubMed ID: 7974341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A clinical study assessing the pharmacokinetics, efficacy and safety of AlphaNine(®) , a high-purity factor IX concentrate, in patients with severe haemophilia B.
    Lissitchkov T; Matysiak M; Zavilska K; Laguna P; Gercheva L; Antonov A; Cabrera N; Aznar JA; Woodward MK; Páez A
    Haemophilia; 2011 Jul; 17(4):590-6. PubMed ID: 21299747
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantitation of seminal factor IX and factor IXa in fertile, nonfertile, and vasectomy subjects: a step closer toward identifying a functional clotting system in human semen.
    Lwaleed BA; Greenfield RS; Hicks J; Birch BR; Cooper AJ
    J Androl; 2005; 26(1):146-52. PubMed ID: 15611579
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High sensitivity detection of activated factor IX: application to the analysis of different therapeutical factor IX concentrates and prothrombin complexes.
    Kusch M; Seitz R; König H
    Thromb Haemost; 1998 Apr; 79(4):778-83. PubMed ID: 9569192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Measurement of activated factor IX in factor IX concentrates: correlation with in vivo thrombogenicity.
    Gray E; Tubbs J; Thomas S; Oates A; Boisclair M; Kemball-Cook G; Barrowcliffe TW
    Thromb Haemost; 1995 Apr; 73(4):675-9. PubMed ID: 7495077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased fibrinopeptide A after prothrombin complex concentrates.
    Viganó S; Cattaneo M; Gervasoni W; Mannucci PM
    Thromb Haemost; 1980 Oct; 44(2):72-5. PubMed ID: 6779400
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of prothrombin complex concentrate on INR and blood coagulation system in emergency patients treated with warfarin overdose.
    Yasaka M; Oomura M; Ikeno K; Naritomi H; Minematsu K
    Ann Hematol; 2003 Feb; 82(2):121-3. PubMed ID: 12601493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombogenic mechanisms in the human: fresh insights obtained by immunodiagnostic studies of coagulation markers.
    Boisclair MD; Philippou H; Lane DA
    Blood Coagul Fibrinolysis; 1993 Dec; 4(6):1007-21. PubMed ID: 8148474
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Biochemical and in vivo properties of high purity factor IX concentrates.
    Berntorp E; Björkman S; Carlsson M; Lethagen S; Nilsson IM
    Thromb Haemost; 1993 Nov; 70(5):768-73. PubMed ID: 8128433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.